HIỆU QUẢ CỦA CILOSTAZOL TRONG ĐIỀU TRỊ ĐAU CÁCH HỔI Ở BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TÍP 2 CÓ BỆNH ĐỘNG MẠCH CHI DƯỚI

Abstract

Background: Patients with type 2 diabetes who suffer from lower extremity peripheral artery disease often experience claudication as a characteristic symptom. Although the benefits of cilostazol in treating intermittent claudication have been proven, research on this issue is still scarce in Vietnam. Objectives: To evaluate the effectiveness of cilostazol in treating claudication in patients with type 2 diabetes and lower extremity peripheral artery disease. Materials and methods: A cross-sectional descriptive study conducted on 35 patients with type 2 diabetes who diagnosed lower extremity peripheral artery disease and treated with cilostazol at Bac Lieu General Hospital from June 2023 to April 2024. Results: The patients had a mean age of 65.2 ± 7.4 years, with the majority aged ≥ 60 years (77.1%), and the male-to-female ratio was roughly equal. Abdominal obesity was present in 82.9% of the subjects, hypertension and smoking account for the majority of patients. Most patients were classified as Fontaine II or III. In the results of the 6-minute walk test, the pain-free walking distance and the maximum walking distance were significantly lower in females and the ≥ 60 age group compared to males and the < 60 age group, with p = 0.001. No significant differences were noted in the ABI across genders and age groups. Treatment outcomes with cilostazol demonstrated significant improvements in subjective functional symptoms of the patients, ABI, walking distance during 6-minute walk test, and Fontaine classification. The majority of patients (71.4%) experienced no drug side effects, and most adhered to the medication for the full 3 months (80.0%). Conclusion: After 3 months of cilostazol treatment, there was significant improvement in the patients’ subjective functional symptoms, ABI, walking distance, and Fontaine classification.